Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Multiple Myeloma Treatment Market Trends, Insights and Size Analysis By Treatment (Chemotherapy, Radiation Therapy, Stem Cell Transplant, Corticosteroids, Interferon, and Others), End User (Hospitals, Clinics, Independent Pharmacies, and Others)โ€”Forecast till 2030


ID: MRFR/Pharma/5354-HCR | 90 Pages | Author: Rahul Gotadki| April 2024
Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porterโ€™s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Multiple Myeloma Treatment Market, by Treatment

6.1 Introduction

6.2 Chemotherapy

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.2.1 Bendamustine (Treanda)

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.2.2 Cyclophosphamide (Cytoxan)

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.2.3 Doxorubicin (Adriamycin)

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.2.4 Etoposide

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.2.5 Liposomal doxorubicin (Doxil)

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.2.6 Melphalan (Alkeran, Evomela)

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.2.7 Vincristine (Oncovin)

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.3 Corticosteroids

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.4 Interferon

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.5 Stem Cell Transplant

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

6.6 Radiation therapy

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

Chapter 7. Global Multiple Myeloma Treatment Market, by End-User

7.1 Introduction

7.2 Hospitals

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

7.3 Clinics

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

7.4 Independent Pharmacies

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

7.5 Other

Market Estimates & Forecast, by Region, 2020โ€“2027

Market Estimates & Forecast, by Country, 2020โ€“2027

Chapter 8. Global Multiple Myeloma Treatment Market, by Region

8.1 Introduction

8.2 Americas

8.2.1 North America

8.2.1.1 US

8.2.1.2 Canada

8.2.2 South America

8.3 Europe

8.3.1 Western Europe

8.3.1.1 Germany

8.3.1.2 France

8.3.1.3 Italy

8.3.1.4 Spain

8.3.1.5 UK

8.3.1.6 Rest of Western Europe

8.3.2 Eastern Europe

8.4 Asia-Pacific

8.4.1 Japan

8.4.2 China

8.4.3 India

8.4.4 Australia

8.4.5 South Korea

8.4.6 Rest of Asia-Pacific

8.5 Middle East & Africa

8.5.1 Middle East

8.5.2 Africa

Chapter 9 Company Landscape

9.1 Introduction

9.2 Market Share Analysis

9.3 Key Development & Strategies

Chapter 10. Company Profiles

10.1 Celgene Corporation

10.1.1 Company Overview

10.1.2 Product Overview

10.1.3 Financials Overview

10.1.4 Key Developments

10.1.5 SWOT Analysis

10.2 Janssen Biotech, Inc.

10.2.1 Company Overview

10.2.2 Product Overview

10.2.3 Financial Overview

10.2.4 Key Developments

10.2.5 SWOT Analysis

10.3 Bristol-Myers Squibb Company

10.3.1 Company Overview

10.3.2 Product Overview

10.3.3 Financial Overview

10.3.4 Key Development

10.3.5 SWOT Analysis

10.4 Novartis AG

10.4.1 Company Overview

10.4.2 Product Overview

10.4.3 Financial Overview

10.4.4 Key Development

10.4.5 SWOT Analysis

10.5 Millennium Pharmaceuticals

10.5.1 Company Overview

10.5.2 Product Overview

10.5.3 Financial overview

10.5.4 Key Developments

10.5.5 SWOT Analysis

10.6 Amgen, Inc

10.6.1 Company Overview

10.6.2 Product Overview

10.6.3 Financial Overview

10.6.4 Key Developments

10.6.5 SWOT Analysis

10.7 Genzyme Corporation

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financial Overview

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 Juno Therapeutics

10.8.1 Overview

10.8.2 Product Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.7 Johnson & Johnson

10.7.1 Overview

10.7.2 Product Overview

10.7.3 Financials

10.7.4 Key Developments

10.7.5 SWOT Analysis

10.8 F. Hoffmann-La Roche Ltd

10.8.1 Overview

10.8.2 Product Overview

10.8.3 Financials

10.8.4 Key Developments

10.8.5 SWOT Analysis

10.11 GlaxoSmithKline plc

10.91 Overview

10.92 Product Overview

10.93 Financials

10.94 Key Developments

10.95 SWOT Analysis

10.10 AbbVie Inc

10.10.1 Overview

10.10.2 Product Overview

10.10.3 Financials

10.10.4 Key Developments

10.10.5 SWOT Analysis

10.13 Innate Pharma SA

10.13.1 Overview

10.13.2 Product Overview

10.13.3 Financials

10.13.4 Key Developments

10.13.5 SWOT Analysis

10.14 Celldex Therapeutics, Inc

10.14.1 Overview

10.14.2 Product Overview

10.14.3 Financials

10.14.4 Key Developments

10.14.5 SWOT Analysis

10.15 Onyx Pharmaceuticals

10.15.1 Overview

10.15.2 Product Overview

10.15.3 Financials

10.15.4 Key Developments

10.15.5 SWOT Analysis

10.16 Pfizer

10.16.1 Overview

10.16.2 Product Overview

10.16.3 Financials

10.16.4 Key Developments

10.16.5 SWOT Analysis

10.17 Takeda Pharmaceuticals

10.17.1 Overview

10.17.2 Product Overview

10.17.3 Financials

10.17.4 Key Developments

10.17.5 SWOT Analysis

Chapter 11 MRFR Conclusion

11.1 Key Findings

11.1.1 From CEOโ€™s Viewpoint

11.1.2 Unmet Needs of the Market

11.2 Key Companies to Watch

11.3 Predictions for the Multiple Myeloma Treatment Market

Chapter 12. Appendix

LIST OF TABLES

Table 1 Global Multiple Myeloma Treatment Market Synopsis, 2020โ€“2027

Table 2 Global Multiple Myeloma Treatment Market Estimates and Forecast, 2020โ€“2027 (USD Million)

Table 3 Global Multiple Myeloma Treatment Market, by Region, 2020โ€“2027 (USD Million)

Table 4 Global Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 5 Global Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 6 North America: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 7 North America: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 8 US: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 9 US: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 10 Canada: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 11 Canada: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 12 South America: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 13 South America: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 14 Europe: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 15 Europe: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 16 Western Europe: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 17 Western Europe: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 18 Eastern Europe: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 19 Eastern Europe: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 20 Asia-Pacific: Multiple Myeloma Treatment Market, by Treatment, 2020โ€“2027 (USD Million)

Table 21 Asia-Pacific: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

Table 22 Middle East & Africa: Multiple Myeloma Treatment Market, by Treatment, 2020-2027 (USD Million)

Table 23 Middle East & Africa: Multiple Myeloma Treatment Market, by End-User, 2020โ€“2027 (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Multiple Myeloma Treatment Market

Figure 3 Segmentation Market Dynamics for Global Multiple Myeloma Treatment Market

Figure 4 Global Multiple Myeloma Treatment Market Share, by Treatment, 2020

Figure 5 Global Multiple Myeloma Treatment Market Share, by End-User, 2020

Figure 6 Global Multiple Myeloma Treatment Market Share, by Region, 2020

Figure 7 North America: Multiple Myeloma Treatment Market Share, by Country, 2020

Figure 8 Europe: Multiple Myeloma Treatment Market Share, by Country, 2020

Figure 9 Asia-Pacific: Multiple Myeloma Treatment Market Share, by Country, 2020

Figure 10 Middle East & Africa: Multiple Myeloma Treatment Market Share, by Country, 2020

Figure 11 Global Multiple Myeloma Treatment Market: Company Share Analysis, 2020 (%)

Figure 12 Celgene Corporation: Key Financials

Figure 13 Celgene Corporation: Segmental Revenue

Figure 14 Celgene Corporation: Geographical Revenue

Figure 15 Janssen Biotech, Inc.: Key Financials

Figure 16 Janssen Biotech, Inc.: Segmental Revenue

Figure 17 Janssen Biotech, Inc.: Geographical Revenue

Figure 18 Bristol-Myers Squibb Company: Key Financials

Figure 19 Bristol-Myers Squibb Company: Segmental Revenue

Figure 20 Bristol-Myers Squibb Company: Geographical Revenue

Figure 21 Novartis AG: Key Financials

Figure 22 Novartis AG: Segmental Revenue

Figure 23 Novartis AG: Geographical Revenue

Figure 24 Millennium Pharmaceuticals: Key Financials

Figure 25 Millennium Pharmaceuticals: Segmental Revenue

Figure 26 Millennium Pharmaceuticals. Geographical Revenue

Figure 27 Amgen, Inc: Key Financials

Figure 28 Amgen, Inc: Segmental Revenue

Figure 29 Amgen, Inc: Geographical Revenue

Figure 30 Genzyme Corporation: Key Financials

Figure 31 Genzyme Corporation: Segmental Revenue

Figure 32 Genzyme Corporation: Geographical Revenue

Figure 33 Juno Therapeutics: Key Financials

Figure 34 Juno Therapeutics: Segmental Revenue

Figure 35 Juno Therapeutics: Geographical Revenue

Figure 36 Johnson & Johnson: Key Financials

Figure 37 Johnson & Johnson: Segmental Revenue

Figure 38 Johnson & Johnson: Geographical Revenue

Figure 39 F. Hoffmann-La Roche Ltd: Key Financials

Figure 40 F. Hoffmann-La Roche Ltd: Segmental Revenue

Figure 41 F. Hoffmann-La Roche Ltd: Geographical Revenue

Figure 42 GlaxoSmithKline plc: Key Financials

Figure 43 GlaxoSmithKline plc: Segmental Revenue

Figure 44 GlaxoSmithKline plc: Geographical Revenue

Figure 45 AbbVie Inc: Key Financials

Figure 46 AbbVie Inc: Segmental Revenue

Figure 47 AbbVie Inc: Geographical Revenue

Figure 48 Innate Pharma SA: Key Financials

Figure 49 Innate Pharma SA: Segmental Revenue

Figure 50 Innate Pharma SA: Geographical Revenue

Figure 51 Celldex Therapeutics, Inc: Key Financials

Figure 52 Celldex Therapeutics, Inc: Segmental Revenue

Figure 53 Celldex Therapeutics, Inc: Geographical Revenue

Figure 54 BrainScope Company, Inc, Inc: Key Financials

Figure 55 BrainScope Company, Inc, Inc: Segmental Revenue

Figure 56 BrainScope Company, Inc, Inc: Geographical Revenue

Figure 57 Pfizer, Inc: Key Financials

Figure 58 Pfizer, Inc: Segmental Revenue

Figure 59 Pfizer, Inc: Geographical Revenue

Figure 60 Takeda Pharmaceuticals, Inc: Key Financials

Figure 61 Takeda Pharmaceuticals, Inc: Segmental Revenue

Figure 62 Takeda Pharmaceuticals, Inc: Geographical Revenue

Figure 63 Onyx Pharmaceuticals: Key Financials

Figure 64 Onyx Pharmaceuticals: Segmental Revenue

Figure 65 Onyx Pharmaceuticals: Geographical Revenue

Figure 66 Silver Creek Pharmaceuticals Inc: Key Financials

Figure 67 Silver Creek Pharmaceuticals Inc: Segmental Revenue

Figure 68 Silver Creek Pharmaceuticals Inc: Geographical Revenue

Figure 69 Stemedica Cell Technologies Inc: Key Financials

Figure 70 Stemedica Cell Technologies Inc: Segmental Revenue

Figure 71 Stemedica Cell Technologies Inc: Geographical Revenue

Figure 72 Banayan Biomarkers Inc: Key Financials

Figure 73 Banayan Biomarkers Inc: Segmental Revenue

Figure 74 Banayan Biomarkers Inc: Geographical Revenue

Figure 75 Vasopharm GmbH: Key Financials

Figure 76 Vasopharm GmbH: Segmental Revenue

Figure 77 Vasopharm GmbH: Geographical Revenue

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.